Antitumor and antiangiogenic effects of interleukin 12 gene therapy in murine head and neck carcinoma model

Auris Nasus Larynx

Volumn 31, Issue 3, 2004, Pages 239-245

  Imagawa, Yukari ^a   Satake, Kenichi ^a   Kato, Yasumasa ^a   Tahara, Hideaki ^b   Tsukuda, Mamoru ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b THE UNIVERSITY OF TOKYO   (Japan)

Author keywords

Antiangiogenesis; Antitumor; Direct intratumoral injection; Gene therapy; Head and neck squamous cell carcinoma; Interleukin 12

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; MESSENGER RNA; RECOMBINANT INTERLEUKIN 12; RETROVIRUS VECTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENE THERAPY; GENETIC TRANSFECTION; HEAD AND NECK CARCINOMA; IN VITRO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; SPLEEN CELL; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TUMOR GROWTH; TUMOR REGRESSION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD56; ANTIGENS, CD8; CARCINOMA, SQUAMOUS CELL; CELL COUNT; CELL LINE, TUMOR; GENE THERAPY; HEAD AND NECK NEOPLASMS; IMMUNOHISTOCHEMISTRY; INJECTIONS; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; RNA, MESSENGER; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 4544337918     PISSN: 03858146     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anl.2004.03.008     Document Type: Article

References (32)

1. Gately M.K., Wolitzky A.G., Quinn P.M., Chizzonite R. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol. 143:1992;127-142
2. McKnight A.J., Zimmer G.J., Fogelman I., Wolf S.F., Abbas A.K. Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol. 152:1994;2172-2179
3. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol. 13:1995;251-276
4. Brunda M.J., Luistro L., Warrier R.R., Wright R.B., Hubbard B.R., Murphy M., et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 178:1993;1223-1230
5. Nastala C.L., Edington H.D., McKinney T.G., Tahara H., Nalesnik M.A., Brunda M.J., et al. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J Immunol. 153:1994;1697-1706
6. Verbik D.J., Stinson W.W., Brunda M.J., Kessinger A., Joshi S.S. In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma. Clin Ex Metastasis. 14:1996;219-229
7. Zou J.P., Yamamoto N., Fujii T., Takenaka H., Kobayashi M., Herrmann S.H., et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-γ production by anti-tumor T cells. Int Immunol. 7:1995;1135-1145
8. Strasly M., Cavallo F., Geuna M., Mitola S., Colombo M.P., Forni G. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol. 166:2001;3890-3899
9. Dias S., Thomas H., Balkwill F. Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model. Int J Cancer. 75:1998;151-157
10. Voest E.E., Kenyon B.M., O'Reilly M.S., Truitt G., D'Amato R.J., Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 87:1995;581-586
11. Tannenbaum C.S., Wicker N., Armstrong D., Tubbs R., Finke J., Bukowski R.M., et al. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol. 156:1996;693-699
12. Rakhmilevich A.L., Turner J., Ford M.J., McCabe D., Sun W.H., Sondel P.M., et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA. 93:1996;6291-6296
13. Leonard J.P., Sherman M.L., Fisher G.L., Buchanan L.J., Larsen G., Atkins M.B., et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 90:1997;2541-2548
14. Atkins M.B., Robertson M.J., Gordon M., Lotze M.T., DeCoste M., DuBois J.S., et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 3:1997;409-417
15. Chen L., Chen D., Block E., O'Donnell M., Kufe D.W., Clinton S.K. Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer. J Immunol. 159:1997;351-359
16. Myers J.N., Mank-Seymour A., Zitvogel L., Storkus W., Clarke M., Johnson C.S., et al. Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. Laryngoscope. 108:1998;261-268
17. Coughlin C.M., Salhany K.E., Wysocka M., Aruga E., Kurzawa H., Chang A.E., et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest. 101:1998;1441-1452
18. Tahara H., Zeh H.J. III, Storkus W.J., Pappo I., Watkins S.C., Gubler U., et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 54:1994;182-189
19. Herr W., Schneider J., Lohse A.W., Meyer zum Buschenfelde K.H., Wolfel T. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods. 191:1996;131-142
20. Asai T., Storkus W.J., Whiteside T.L. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin Diagn Lab Immunol. 7:2000;145-154
21. Meidenbauer N., Harris D.T., Spitler L.E., Whiteside T.L. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate. 43:2000;88-100
22. Asselin-Paturel C., Lassau N., Guinebretiere J.M., Zhang J., Gay F., Bex F., et al. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther. 6:1999;606-615
23. Mendiratta S.K., Quezada A., Matar M., Wang J., Hebel H.L., Long S., et al. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity. Gene Ther. 6:1999;833-839
24. Dow S.W., Elmslie R.E., Fradkin L.G., Liggitt D.H., Heath T.D., Willson A.P., et al. Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases. Hum Gene Ther. 10:1999;2961-2972
25. Puisieux I., Odin L., Poujol D., Moingeon P., Tartaglia J., Cox W., et al. Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity. Hum Gene Ther. 9:1998;2481-2492
26. Yao L., Sgadari C., Furuke K., Bloom E.T., Teruya-Feldstein J., Tosato G. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood. 93:1999;1612-1621
27. Chan S.H., Perussia B., Gupta J.W., Kobayashi M., Pospisil M., Young H.A., et al. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med. 173:1991;869-879
28. Frucht D.M., Fukao T., Bogdan C., Schindler H., O'Shea J.J., Koyasu S. IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol. 22:2001;556-560
29. Schreiber R.D., Farrar M.A., Hershey G.K., Fernandez-Luna J. The structure and function of interferon-gamma receptors. Int J Immunopharmacol. 14:1992;413-419
30. Tsung K., Meko J.B., Peplinski G.R., Tsung Y.L., Norton J.A. IL-12 induces T helper 1-directed antitumor response. J Immunol. 158:1997;3359-3365
31. Yu W.G., Ogawa M., Mu J., Umehara K., Tsujimura T., Fujiwara H., et al. IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways. J Leukoc Biol. 62:1997;450-457
32. Tsukuda M., Mochimatsu I., Sakumoto M., Furukawa S., Yuyama S., Yanoma S., et al. Autologous tumor cell killing activity of tumor-associated lymphocytes in patients with head and neck carcinomas. Biotherapy. 6:1993;155-161